Citigroup’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-30,466
| Closed | -$1.02M | – | 6066 |
|
|
2024
Q3 | $1.02M | Buy |
30,466
+19,995
| +191% | +$688K | ﹤0.01% | 3250 |
|
|
2024
Q2 | $283K | Buy |
10,471
+387
| +4% | +$7.63K | ﹤0.01% | 3715 |
|
|
2024
Q1 | $218K | Buy |
10,084
+7,832
| +348% | +$171K | ﹤0.01% | 3983 |
|
|
2023
Q4 | $13.6K | Buy |
2,252
+2,245
| +32,071% | +$11.2K | ﹤0.01% | 5115 |
|
|
2023
Q3 | $39 | Sell |
7
-4,631
| -100% | -$29.8K | ﹤0.01% | 5546 |
|
|
2023
Q2 | $34K | Buy |
4,638
+1,870
| +68% | +$14.2K | ﹤0.01% | 4817 |
|
|
2023
Q1 | $10.9K | Buy |
+2,768
| New | +$13.5K | ﹤0.01% | 4697 |
|
|
2022
Q4 | – | Sell |
-112,605
| Closed | -$419K | – | 6220 |
|
|
2022
Q3 | $419K | Sell |
112,605
-212,395
| -65% | -$784K | ﹤0.01% | 3367 |
|
|
2022
Q2 | $1M | Buy |
325,000
+170,207
| +110% | +$783K | ﹤0.01% | 2639 |
|
|
2022
Q1 | $803K | Sell |
154,793
-45,207
| -23% | -$214K | ﹤0.01% | 3153 |
|
|
2021
Q4 | $968K | Buy |
+200,000
| New | +$1.36M | ﹤0.01% | 3300 |
|
|
2021
Q2 | – | Sell |
-405,645
| Closed | -$6.62M | – | 6635 |
|
|
2021
Q1 | $6.62M | Buy |
+405,645
| New | +$6.63M | ﹤0.01% | 1619 |
|
Citigroup's LBPH Position: Q4 2024 in Review
Citigroup sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 30,466 shares — an estimated $1.02M sold.
Citigroup first reported a position in LBPH in Q1 2021 and held it in 12 quarters. The position peaked at $6.62M in Q1 2021. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Citigroup reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Citigroup sold 30,466 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.02M.
- Citigroup first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Citigroup's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $6.62M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.